EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Expression and prognostic impact of CD73 in classical Hodgkin lymphoma

Beichen Liu, Cuiying He, Haisheng Liu, Guangyu Ma, Shuo Zhang, Yan Liu, Caili Liu, Kexin Li, Yunzhe Wang, Yueping Liu, Meng Yue, Chang Liu und 3 weitere

Annals of Hematology · 21.04.2026 · 105 (5)

DOI: 10.1007/s00277-026-06987-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 21.04.2026. Verfasst von Beichen Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, The Fourth Hospital of Hebei Medical University, Shijiaz…. Hauptthemen laut MEDLINE: Hodgkin Disease, 5'-Nucleotidase, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Key Project of Hebei Provincial Health and Family Planning Commission Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a clinical challenge, underscoring the need for early identification of high-risk patients to guide treatment stratification. CD73, an ectoenzyme involved in adenosine production, plays a key role in immunosuppression and tumor progression. While elevated CD73 expression has been linked to poor prognosis in many cancers, its role in cHL has not been fully elucidated. In this retrospective case-control study, we evaluated the baseline expression of CD73, CD39, and PD-L1 in newly diagnosed cHL patients and explored their association with treatment outcomes. A total of 84 patients were followed after first-line therapy and retrospectively categorized into a relapsed/refractory (r/r) group (n = 47) and a non-r/r group (n = 37). CD73 expression was significantly lower in the r/r group compared to the non-r/r group. Patients with low CD73 expression had inferior complete response rates and shorter progression-free survival (PFS). On multivariate analysis, low CD73 expression remained an independent adverse prognostic factor for PFS (hazard ratio: 3.321, 95% CI: 1.384–7.967). These findings suggest that baseline CD73 expression may serve as a prognostic biomarker for relapse risk and long-term outcomes in cHL, with potential implications for individualized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin Disease5'-NucleotidaseBiomarkers, TumorGene Expression Regulation, NeoplasticHumansFemaleMalePrognosisRetrospective StudiesAdultMiddle AgedGPI-Linked ProteinsCase-Control StudiesAgedYoung Adult

Stichwörter der Autor:innen

CD73Classical Hodgkin lymphomaImmune checkpoint inhibitorPrognostic factorRelapsed/refractory lymphoma

Substanzen

5'-NucleotidaseNT5E protein, humanGPI-Linked ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Otolaryngology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. lixixi616@sina.com.

Förderung

  • the Key Project of Hebei Provincial Health and Family Planning Commission Fund

Zitieren

APA

Liu, B., He, C., Liu, H., Ma, G., Zhang, S., Liu, Y., Liu, C., Li, K., Wang, Y., Liu, Y., Yue, M., Liu, C., Wang, X., Yin, S., & Li, Z. (2026). Expression and prognostic impact of CD73 in classical Hodgkin lymphoma. Annals of Hematology, 105(5). https://doi.org/10.1007/s00277-026-06987-1

Vancouver

Liu B, He C, Liu H, Ma G, Zhang S, Liu Y, et al. Expression and prognostic impact of CD73 in classical Hodgkin lymphoma. Annals of Hematology. 2026;105(5). doi:10.1007/s00277-026-06987-1

BibTeX
@article{Liu2026,
  author = {Liu, Beichen and He, Cuiying and Liu, Haisheng and Ma, Guangyu and Zhang, Shuo and Liu, Yan and Liu, Caili and Li, Kexin and Wang, Yunzhe and Liu, Yueping and Yue, Meng and Liu, Chang and Wang, Xiaoxiao and Yin, Shaoning and Li, Zheng},
  title = {Expression and prognostic impact of CD73 in classical Hodgkin lymphoma},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {5},
  doi = {10.1007/s00277-026-06987-1}
}
Kostenlos starten →